Thursday, 3 July 2014

Tuberculosis TB disease rate increased in Washington

Thursday, July 03, 2014 Leave a Comment

The rate of tuberculosis TB disease increases in Washington

Tuberculosis cases has risen dramatically in Washington for the first time after several years of decline. 

Tuberculosis cases has risen dramatically in Washington for the first time after several years of decline.

Up to 13 percent of the 185 cases reported in 2012- the last year, 209 cases of tuberculosis (TB) were recorded. 

The tuberculosis rate in Washington has always been lower than the national average, but in 2013 its rate is higher corresponded to the national average. 

"TB can be very serious and even fatal disease. Treatment is difficult for people because it requires taking multiple medications for several months," State Board of Health said Dr. Kathy Lofy. 

"It is important for public health and the health of the community to remain vigilant and work together to fight against TB." 

TB is a dangerous disease. This is usually a bacterial infection which affects the lungs but attack other parts of the body. 

Most symptoms are fever, night sweats, fatigue, weight loss and a persistent cough. 

Some people can be infected with TB and have no symptoms. 

Immediate treatment with appropriate antibiotics is the key to survival and less severe symptoms. 

People with HIV or AIDS, people under 5 and over 50, and people whose immune systems are most at risk. 

The disease is spread through the air when an infected person coughs, sneezes or speaks, and breathe in other bacteria. 

Counties with the largest number of cases in 2013 were the king (114), Snohomish (26), Pierce (22), Spokane (7), Clark (5) and Thurston (5). 

Drug-resistant TB remains a threat to public health in Washington. This type of treatment of tuberculosis requires a longer period of time. 

Two cases resistant to the Department of State Health TB multi-drug were reported in 2013. 

Infection control procedures must prevent, so it does not spread in place in hospitals or care to avoid exposure to TB. 

TB are higher among racial and ethnic groups. Nearly 75 percent of 2,013 cases born in the state abroad. 

In 2013, 53.6 percent of all reported cases of tuberculosis in Washington were among Asians, followed by Hispanics (13.9 percent) and white (13.4 percent). 

American Indians and Alaska accounted for only 1.4 percent of TB cases in Washington in 2013. 

Health care providers, laboratory workers and health agencies must continue to work together to prevent the recurrence of tuberculosis. There are only 75 years, tuberculosis has killed nearly 1,000 state residents each year. In 2013, there were 16 deaths from TB. 

The disease burden continues to rise, especially in drug-resistant cases are becoming more common around the world. 

Also read:

While considerable work has been done to prevent the spread of the disease, tuberculosis is a long-term commitment that must be respected by the community health care and public health. 

Worldwide TB is a leading cause of death from infectious diseases. About nine million people infected with TB worldwide each year, and kills about two million.
Read More
Thursday, 19 June 2014

Designer T-cells Clear autoimmune disease, without immune side effect

Thursday, June 19, 2014 Leave a Comment

Designer T-cells Clear autoimmune disease, without weakening the immune system

Successfully tested in mice, could this protocol lead to new ways to treat autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and type 1 diabetes in people.

This protocol lead to new ways to treat autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and type 1 diabetes in people.
Designer T-cells Clear autoimmune disease

Currently, the main treatment for autoimmune diseases comprising the suppression of inflammation by blocking the immune cells with anti-inflammatory drugs and steroids. While temporarily relieve the symptoms, these drugs can inhibit the immune system at the same time and leave the patient vulnerable to certain infections.

Therefore, scientists are trying a new type of treatment that target autoimmune and inflammatory immune cells without disturbing the immune system. Thus the power of immune system remains unaffected with this type of treatment.

New research highlighted in Science Translational Medicine, explains how researchers have developed specific T cells pathogenic immune cells without destroying immune system.

Facts about autoimmune diseases

Redesigning the immune system

The research was carried out and discovered by Shinpei Kasagi by the National Institutes of Health (NIH). Researchers have created an environment of immuno suppressed mice or experimental autoimmune encephalomyelitis with non-obese diabetes or an immune molecule with the call control of TGF-beta. Autoantigenic peptides were then injected in the animals; These peptides are the molecules to create the specific regulatory T cells and found in the differentiation of T cells specific for the antigen.

Regulatory T cells and inflammatory then allowed to go in the tissues and organs of mice. In essence the researchers, redesigned the immune system with regulatory T cells.

Scientists have found that regulatory newly generated T cells not only stopped the autoimmune disease, but the animals have remained free of disease after stopping the injection of peptides.

The key to the treatment is the insertion of T-cell auto-antigens specific regulator. The methods have been developed to reprogram differentiating T cells in native immune suppressor regulatory T cells, not T-cell pro-inflammatory effector cells, said Dr. Wanjun Chen, an NIH researcher. Once programmed, these autoantigens specific regulatory T-cells to regenerate, which is probably why the mice in the study continued to experience a remission after treatment.

It remains to be confirmed that it will be administered by the long-term remission of several peptides, Chen said.

"The efficacy and long-term and dramatic suppression of autoimmune diseases is better than expected," Chen said.

After treatment, the mice with normal immune system, bacterial antigens were suspended.

Looking to the future

What's next for this approach? The researchers say that they want to judge them, such as regulatory T cells work in animals with other autoimmune diseases such as arthritis, before clinical trials in humans.

Theoretically, the protocol could be used for other types of autoimmune diseases in mice and eventually in humans as a researcher identifies one or more autoantigens specific for the particular disease.

You may also like

"Maybe the type 1 diabetes and MS are diseases that need to be explored first," Chen said in a statement.

For now, Chen said, represents a big step toward the "holy grail" of immunology research, namely, how immune cells specifically without weakening the immune system of a patient.
Read More
Saturday, 31 May 2014

Elelyso new drug to treat Gaucher and pediatric patients in Canada

Saturday, May 31, 2014 Leave a Comment

Protalix Announces ELELYSO (TM) (taliglucerase alfa) in Canada for the treatment of Gaucher disease in adults and pediatric patients

Protalix BioTherapeutics, Inc. (NYSE MKT : PLX) (TASE: PLX) today announced that Health Canada has approved for ELELYSO ™ (taliglucerase alfa for injection) for the long-term Enzym replacement therapy for the adult patients and pediatric patients with a confirmed diagnosis of type1 Gaucher disease. ELELYSO and hematologic manifestations in pediatric patients Gaucher's disease diagnosis can be used with a confirmed diagnosis of Type3. ELELYSO be marketed in Canada by Pfizer Inc by the marketing partner of the company.

Protalix Announces ELELYSO (TM) (taliglucerase alfa) in Canada for the treatment of Gaucher disease in adults and pediatric patients

                      ELELYSO injections

"With the approval of ELELYSO in Canada, this drug can be uded for patients in more than ten countries approved worldwide," said Dr. Einat Brill Almon, vice president of product development Protalix. " This confirms the capacity and safety of ProCellEx®, our technology platform currently used to develop additional enzyme replacement therapies."


ELELYSO™ (taliglucerase alfa) for injection is a lysosomal enzyme glucocerebrosidase - as replacement therapy for certain long-term enzymatic replacement therapy (ERT) for Gaucher's disease in adults with a confirmed diagnosis of Type 1 displayed .

Important Safety Considerations for U.S. for the ELELYSO drug

As with all injectable protein product, such as enzyme replacement therapy (ERT) , there were observed severe allergic reactions (including anaphylaxis) in patients treated with ELELYSO. When this happens, ELELYSO should be immediately discontinued and appropriate medical therapy should be consulted. Patients who have suffered anaphylaxis or other ELELYSO ERT, should be careful in the use of this drug.

In addition, injection site reactions (including allergic reactions) are defined as a reaction that occurs within 24 hours after the infusion- reactions were the most frequently observed with ELELYSO. The most commonly reported reactions were headache infusion, pain or discomfort, weakness, fatigue, hives, abnormal redness of the skin, increased blood pressure, back or joint pain, skin rash and chest. Other infusion reactions or allergic reactions are swelling of the face, mouth or throat; wheezing; shortness of breath; Turning bluish color of the skin; cough; and low blood pressure. Most of these reactions were mild and require no treatment.

Infusion reactions management is of the type and severity of the reaction. Your doctor may deal with treat temporarily reactions associated with the infusion to stop the infusion or to slow the rate of infusion, or treated with medications such as antihistamines. Treatment with antihistamines or corticosteroids prior to infusion with ELELYSO can prevent these reactions.

Other common adverse events were infections of the upper respiratory tract infection, sore throat, flu, urinary tract infection and pain in the limbs.

As with all therapeutic proteins, including teams of experts, the possibility of developing antibodies to ELELYSO. However, it is still unclear whether this has an impact on clinical response or adverse effects. Patients with an immune response to other teams of experts contact ELELYSO should continue to monitor the antibody. By comparing the frequency of antibodies by expert teams can be misleading. Patients with infusion-related reactions or immune ELELYSO or other ERT is developed should be monitored for antibodies to the drug when treated with ELELYSO.

If you are pregnant or plan to become pregnant, discuss with your doctor for the benefits and to reduce the potential risks.

The health information contained herein is not intended for and replace discussions with a doctor for learning purposes. All decisions regarding patient care must be made with a physician, taking into account the specific characteristics of the patient.

This product information is intended only for residents of the United States.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit , or call 1-800-1088.

About Gaucher

Gaucher disease is an inherited lysosomal storage disorder in humans, affecting approximately 10,000 people worldwide and can cause severe and debilitating symptoms such as enlargement of the liver and spleen. Various forms of diseases of bone, bruising easily create and anemia (lack of red blood cells). Gaucher disease consists of varying degrees of severity; Types 1, 2 and 3 - in accordance with the presence or absence of neurological involvement was divided into three sub-types. Type 1, the most common is at a higher frequency in people who are Ashkenazi Jewish ancestry .
Read More
© 2014 All Rights Reserved.
Health Fitness Blog Sexual Health Cure and Beauty Tips & Powered By BloggerHero